Table 1 Participant characteristics
Characteristic | Venous sampling (n = 148) | Capillary sampling (n = 299) |
|---|---|---|
Gender | ||
Female | 102 (68.9%) | 191 (63.9%) |
Male | 46 (31.1%) | 108 (36.1%) |
Age, median (IQR) | 40 (30–50) | 48 (39–60) |
Ethnicity | ||
White (British/Irish) | 107 (72.3%) | 166 (89.3%) |
White (Other) | 4 (2.7%) | 18 (9.1%) |
Mixed | 1 (0.7%) | 2 (1.0%) |
Black (African) | 0 (0%) | 2 (1.0%) |
Black (Caribbean) | 0 (0%) | 3 (1.5%) |
Asian | 3 (2.0%) | 3 (1.5%) |
Other (not specified) | 36 (24.3%) | 3 (1.5%) |
Vaccine status | ||
Vaccinateda | 143 (96.5%) | 228 (76.3%) |
Unvaccinated | 5 (3.5%) | 71 (23.7%) |
Weeks from COVID-19 vaccination to blood draw, median (IQR) | 7.71 (4.3–16.5) | 13.4 (9.9–16.5) |
Infection status | ||
Prior infectionb | 64 (43.2%) | 80 (26.8%) |
No evidence of infection | 84 (56.8%) | 219 (73.2%) |
Weeks from positive COVID-19 test to blood draw, median (IQR) | 39.9 (9.2–82.2) | 17.4 (11.2–45.2) |
Co-morbidities | ||
None | 148 (100%) | 223 (74.6%) |
Hypothyroid | 0 (0%) | 16 (5.4%) |
Arthritis | 0 (0%) | 14 (4.7%) |
Diabetes | 0 (0%) | 11 (3.7%) |
Cancer | 0 (0%) | 9 (3.0%) |
Colitis | 0 (0%) | 4 (1.3%) |
Lyme disease | 0 (0%) | 3 (1.0%) |
Lupus SLE | 0 (0%) | 2 (0.7%) |
Osteroporosis | 0 (0%) | 2 (0.7%) |
Otherc | 0 (0%) | 17 (5.7%) |
